Steps in the evaluation processNotification of receipt of application - These notices provide advice that a DIR licence application has been received by the OGTR and that a RARMP is in preparation.
Public calls for comment - The Regulator has invited the public to provide comment on a RARMP regarding the identified risk(s) to human health and the environment and the proposed management measures.
Call for comment closed - Comments on these RARMPs have closed, the Regulator is considering submissions and a decision on the licence is imminent.
For more information about DIR applications, please contact the OGTR. DIR applications are available on request (excluding any information that the Regulator has declared to be, or is under consideration as, Confidential Commercial Information) to anyone that requests a copy (section 54 of the Act). A summary of application and, once prepared, the RARMP for each application is available on this website.
|DIR Licence Application Number||Title of Project||Notification of receipt of application||Public calls for comment on RARMP open||Call for comment closed (under consideration by the Regulator)||Is application being assessed as ‘limited and controlled’?|
|DIR 179||Clinical trial with a genetically modified Vaccinia virus vaccine to treat solid cancerous tumours||17 Nov 2020||Yes|
|DIR 177||Clinical trial of genetically modified human adenovirus for bladder cancer treatment||10 Sep 2020||17 Nov 2020||Yes|
|DIR 176||Limited and controlled release of white clover genetically modified for increased condensed tannins||09 Sep 2020||16 Nov 2020||Yes|
|DIR 175||Commercial release of canola (Brassica napus) genetically modified for herbicide tolerance and a hybrid breeding system (MS11)||13 Oct 2020||No|
|DIR 174||Commercial supply of a genetically modified cholera vaccine, VaxchoraŽ||27 May 2020||22 Sep 2020||17 Nov 2020||No|
View the list of DIRs.